DK1185294T3 - Peptides for the treatment of attenuated interpersonal and behavioral disorders - Google Patents
Peptides for the treatment of attenuated interpersonal and behavioral disordersInfo
- Publication number
- DK1185294T3 DK1185294T3 DK00947924T DK00947924T DK1185294T3 DK 1185294 T3 DK1185294 T3 DK 1185294T3 DK 00947924 T DK00947924 T DK 00947924T DK 00947924 T DK00947924 T DK 00947924T DK 1185294 T3 DK1185294 T3 DK 1185294T3
- Authority
- DK
- Denmark
- Prior art keywords
- disorders
- treatment
- interpersonal
- environment
- attenuated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Radiation-Therapy Devices (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
The invention relates to the field of psychopharmacology. More particularly, the invention relates to the treatment of DSM-III disorders, such as impaired interpersonal and behavioral disorders, including sexual disorders such as M.E.D. and HS.D.D. The invention provides new therapeutic compositions and methods for treating DSM-III disorders, including M.E.D. and H.S.D.D. The compositions and methods according to the invention provide improved awareness and alertness to environment, improved adaptation to environment and ability to sustain attention, and increased interest in environment and capacity for arousal, without increased aggressiveness.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14056399P | 1999-06-23 | 1999-06-23 | |
PCT/EP2000/006259 WO2001000221A2 (en) | 1999-06-23 | 2000-06-22 | Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders |
EP00947924A EP1185294B1 (en) | 1999-06-23 | 2000-06-22 | Peptides for the treatment of impaired interpersonal and behavioral disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1185294T3 true DK1185294T3 (en) | 2005-08-01 |
Family
ID=22491816
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05006494T DK1593387T3 (en) | 1999-06-23 | 2000-06-22 | Compositions for the treatment of uninhibited interpersonal and behavioral disorders |
DK00947924T DK1185294T3 (en) | 1999-06-23 | 2000-06-22 | Peptides for the treatment of attenuated interpersonal and behavioral disorders |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05006494T DK1593387T3 (en) | 1999-06-23 | 2000-06-22 | Compositions for the treatment of uninhibited interpersonal and behavioral disorders |
Country Status (14)
Country | Link |
---|---|
US (2) | US7387778B2 (en) |
EP (2) | EP1185294B1 (en) |
JP (1) | JP2003512302A (en) |
CN (1) | CN1189211C (en) |
AT (2) | ATE414529T1 (en) |
AU (1) | AU6154700A (en) |
CA (1) | CA2376935A1 (en) |
CY (1) | CY1108745T1 (en) |
DE (2) | DE60040878D1 (en) |
DK (2) | DK1593387T3 (en) |
ES (2) | ES2315753T3 (en) |
NZ (1) | NZ516477A (en) |
PT (2) | PT1185294E (en) |
WO (1) | WO2001000221A2 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6589750B2 (en) * | 1997-02-20 | 2003-07-08 | Institut Pasteur | Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives |
DE60040878D1 (en) | 1999-06-23 | 2009-01-02 | Pasteur Institut | Compositions for the treatment of impaired interpersonal disorders and behavioral disorders |
DK1216707T3 (en) * | 2000-12-22 | 2005-05-09 | Pasteur Institut | Method for screening ligand molecules that specifically bind to the NEP binding sites of the QHNPR pentapeptide |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
DE602004007105T2 (en) | 2003-01-28 | 2008-02-28 | Microbia Inc., Cambridge | COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISORDER |
HUE016435T4 (en) | 2004-03-19 | 2017-01-30 | Pasteur Institut | Peptides derived from human BPLP protein, polynucleotides coding for said peptides and antibodies directed against said peptides |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
AU2008261102B2 (en) | 2007-06-04 | 2013-11-28 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
RU2542365C2 (en) * | 2008-04-07 | 2015-02-20 | Энститю Пастёр | Opiorphin peptide derivatives as potential inhibitors of ectopeptidases, participating in degradation of enkephalins |
FR2931362B1 (en) | 2008-05-26 | 2017-08-18 | Pasteur Institut | OPIORPHINE FOR USE AS A PSYCHOSTIMULANT. |
EP2328910B1 (en) | 2008-06-04 | 2014-08-06 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
CA2645452A1 (en) * | 2008-11-28 | 2010-05-28 | Institut Pasteur | Use of basic prolin-rich lacrimal gene products, such as opiorphin, as a biomarker |
CA2745694C (en) | 2008-12-03 | 2018-03-27 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase c agonists and methods of use |
DE102009039655B3 (en) | 2009-09-02 | 2011-03-31 | ITT Mfg. Enterprises, Inc., Wilmington | UV disinfection device for waste water and drinking water with a cleaning device |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
MX357121B (en) | 2011-03-01 | 2018-06-27 | Synergy Pharmaceuticals Inc Star | Process of preparing guanylate cyclase c agonists. |
WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
BR112015030326A2 (en) | 2013-06-05 | 2017-08-29 | Synergy Pharmaceuticals Inc | ULTRAPURE GUANYLATE CYCLASE C AGONISTS, METHOD OF MANUFACTURING AND USING THEM |
GB201607814D0 (en) | 2016-05-04 | 2016-06-15 | 5D Health Prot Group Ltd | Anti-microbial compositions |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8327966D0 (en) * | 1983-10-19 | 1983-11-23 | Nyegaard & Co As | Chemical compounds |
FR2637600B1 (en) * | 1988-10-11 | 1992-03-06 | Pasteur Institut | PEPTIDES AND POLYPEPTIDES FROM THE RAT SUB-MAXILLARY GLAND, CORRESPONDING MONOCLONAL AND POLYCLONAL ANTIBODIES, HYBRIDOMAS AND APPLICATIONS THEREOF FOR DIAGNOSIS, DETECTION OR THERAPEUTIC PURPOSES |
US5589189A (en) * | 1994-09-14 | 1996-12-31 | Nexstar Pharmaceuticals, Inc. | Liposome dispersion |
US6589750B2 (en) * | 1997-02-20 | 2003-07-08 | Institut Pasteur | Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives |
KR100353014B1 (en) * | 1998-11-11 | 2002-09-18 | 동아제약 주식회사 | Pyrazolopyrimidinone derivatives for the treatment of impotence |
US6455564B1 (en) * | 1999-01-06 | 2002-09-24 | Pharmacia & Upjohn Company | Method of treating sexual disturbances |
DE60040878D1 (en) | 1999-06-23 | 2009-01-02 | Pasteur Institut | Compositions for the treatment of impaired interpersonal disorders and behavioral disorders |
DK1216707T3 (en) | 2000-12-22 | 2005-05-09 | Pasteur Institut | Method for screening ligand molecules that specifically bind to the NEP binding sites of the QHNPR pentapeptide |
-
2000
- 2000-06-22 DE DE60040878T patent/DE60040878D1/en not_active Expired - Lifetime
- 2000-06-22 WO PCT/EP2000/006259 patent/WO2001000221A2/en active IP Right Grant
- 2000-06-22 DE DE60019106T patent/DE60019106T2/en not_active Expired - Lifetime
- 2000-06-22 JP JP2001505930A patent/JP2003512302A/en active Pending
- 2000-06-22 DK DK05006494T patent/DK1593387T3/en active
- 2000-06-22 AU AU61547/00A patent/AU6154700A/en not_active Abandoned
- 2000-06-22 ES ES05006494T patent/ES2315753T3/en not_active Expired - Lifetime
- 2000-06-22 PT PT00947924T patent/PT1185294E/en unknown
- 2000-06-22 CA CA002376935A patent/CA2376935A1/en not_active Abandoned
- 2000-06-22 CN CNB008092958A patent/CN1189211C/en not_active Expired - Fee Related
- 2000-06-22 NZ NZ516477A patent/NZ516477A/en not_active IP Right Cessation
- 2000-06-22 EP EP00947924A patent/EP1185294B1/en not_active Expired - Lifetime
- 2000-06-22 EP EP05006494A patent/EP1593387B1/en not_active Expired - Lifetime
- 2000-06-22 AT AT05006494T patent/ATE414529T1/en active
- 2000-06-22 ES ES00947924T patent/ES2238299T3/en not_active Expired - Lifetime
- 2000-06-22 AT AT00947924T patent/ATE291927T1/en active
- 2000-06-22 DK DK00947924T patent/DK1185294T3/en active
- 2000-06-22 PT PT05006494T patent/PT1593387E/en unknown
-
2001
- 2001-12-21 US US10/024,535 patent/US7387778B2/en not_active Expired - Fee Related
-
2002
- 2002-12-10 US US10/315,445 patent/US20030186870A1/en not_active Abandoned
-
2009
- 2009-01-16 CY CY20091100058T patent/CY1108745T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP1593387B1 (en) | 2008-11-19 |
US20030186870A1 (en) | 2003-10-02 |
DE60019106T2 (en) | 2006-02-16 |
PT1593387E (en) | 2009-03-18 |
WO2001000221A2 (en) | 2001-01-04 |
CA2376935A1 (en) | 2001-01-04 |
JP2003512302A (en) | 2003-04-02 |
CY1108745T1 (en) | 2014-04-09 |
AU6154700A (en) | 2001-01-31 |
WO2001000221A3 (en) | 2001-05-03 |
ATE291927T1 (en) | 2005-04-15 |
CN1189211C (en) | 2005-02-16 |
DE60040878D1 (en) | 2009-01-02 |
NZ516477A (en) | 2004-02-27 |
EP1185294B1 (en) | 2005-03-30 |
US7387778B2 (en) | 2008-06-17 |
EP1593387A1 (en) | 2005-11-09 |
ES2315753T3 (en) | 2009-04-01 |
ES2238299T3 (en) | 2005-09-01 |
EP1185294A2 (en) | 2002-03-13 |
US20030078200A1 (en) | 2003-04-24 |
ATE414529T1 (en) | 2008-12-15 |
DE60019106D1 (en) | 2005-05-04 |
PT1185294E (en) | 2005-08-31 |
DK1593387T3 (en) | 2009-03-02 |
CN1356906A (en) | 2002-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1108745T1 (en) | PATIENTS FOR THERAPEUTIC PATIENTS BAD BEHAVIOR BETWEEN PERSONS | |
TW200510416A (en) | P38 inhibitors and methods of use thereof | |
HRP20020593B1 (en) | Brain, spinal and nerve injury treatment | |
WO2004019884A3 (en) | Agents and methods for enhancing bone formation | |
HK1080467A1 (en) | Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders | |
NO20050851L (en) | Caspase Inhibitors and Uses thereof | |
SE9803710D0 (en) | Use of certain drugs for treating nerve root injury | |
CY1112238T1 (en) | ANTI-KINESIN SUSPENSIONS AND METHODS OF USING THESE | |
ATE433973T1 (en) | AZOLYLAMINOAZINES AS INHIBITORS OF PROTEIN KINASES | |
ATE325612T1 (en) | USE OF HYDROXYETHYL RUTOSIDES TO TREAT COLD SYMPTOMS, ALLERGIC RHINITIS SYMPTOMS AND RESPIRATORY INFECTIONS | |
ATE430193T1 (en) | RECOMBINANT ALPHA-L-IDURONIDASE AND TREATMENT OF DEFICIENCY DISEASES CAUSED BY IT | |
MXPA04001187A (en) | Interleukin-1 receptors in the treatment of diseases. | |
TNSN06403A1 (en) | 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF | |
WO2005020928A3 (en) | Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins | |
MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
DE60008753D1 (en) | USE OF NAALADASE INHIBITORS FOR THE TREATMENT OF ANXIETIES AND MEMORY DISORDER | |
ATE541565T1 (en) | TOPICAL USE OF MUSCARINIC AND OPIOID AGENTS FOR THE TREATMENT OF TINNITUS | |
DE602004028574D1 (en) | COMPOSITIONS AND METHODS FOR TREATING IRRITATION SYNDROME AND NONULCEREOUS DYSPEPSY | |
TR200200278T2 (en) | Calcilitic compositions | |
DE60142786D1 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANDIDOSES | |
MXPA04010816A (en) | New uses of substituted aminoalkanephosphonic acids. | |
RS20060023A (en) | Use of soluble cd164 in inflammatory and/or autoimmune disorders | |
UA85187C2 (en) | 2-aminobenzoyl derivatives | |
TW200501958A (en) | A therapeutic agent for treating a behavioral disorder | |
ATE399544T1 (en) | SYNERGISTIC COMPOSITION CONTAINING ROFLUMILAST AND (R,R)-FORMOTEROL |